l-Methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 4, 2006, Pages 675-688

  He, Shuangteng ^a   Grasing, Kenneth ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Clorgyline; Dependence syndrome; Methamphetamine; Monoamine oxidase; Morphine; Opioid related disorders; Progressive ratio schedule; Rasagiline; Reinforcement; Selegiline; Self administration; Withdrawal

Indexed keywords

CLORGYLINE; METHAMPHETAMINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MORPHINE SULFATE; PSYCHOSTIMULANT AGENT; RASAGILINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SELF ADMINISTRATION; ENZYME INHIBITION; LOW DRUG DOSE; MALE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RAT; REINFORCEMENT; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; CLORGYLINE; CONDITIONING, OPERANT; EXTINCTION, PSYCHOLOGICAL; INDANS; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; MORPHINE; MORPHINE DEPENDENCE; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SELEGILINE; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; RATTUS;

EID: 33846429588     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.10.022     Document Type: Article

References (38)

1. Ary M., Cox B., and Lomax P. Dopaminergic mechanisms in precipitated withdrawal in morphine-dependent rats. J Pharmacol Exp Ther 200 (1977) 271-276
2. Caine S.B., Lintz R., and Koob G.F. Intravenous drug self-administration techniques in animals. In: Sahgal A. (Ed). Behavioral neuroscience: a practical approach (1993), Oxford University Press, Oxford 117-143
3. Celada P., and Artigas F. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn-Schmiedebergs Arch Pharmacol 347 (1993) 583-590
4. Cohen C., Curet O., Perrault G., and Sanger D.J. Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav 64 (1999) 535-539
5. Felner A.E., and Waldmeier P.C. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28 (1979) 995-1002
6. Finberg J.P., and Youdim M.B. Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 22 (1983) 441-446
7. Garrick N.A., and Murphy D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72 (1980) 27-33
8. George T.P., Vessicchio J.C., Termine A., Jatlow P.I., Kosten T.R., and O'Malley S.S. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53 (2003) 136-143
9. Gerlach M., Youdim M.B.H., and Riederer P. Pharmacology of selegiline. Am Acad Neurol 47 (1996) S137-S143
10. Gerrits M.A., Petromilli P., Westenberg H.G., Di Chiara G., and Van Ree J.M. Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats. Brain Res 924 (2002) 141-150
11. Grasing K., and He S. Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol 16 (2005) 1-13
12. Grasing K., Li N., He S., Parrish C., Delich J., and Glowa J. A new progressive ratio schedule for support of morphine self-administration in opiate dependent rats. Psychopharmacology 168 (2003) 387-396
13. Grasing K., He S., and Li N. Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal. Pharmacol Res 51 (2005) 69-78
14. Green A.R., and Youdim M.B. Use of a behavioural animal model to study the action of monoamine oxidase inhibition in vivo. Monoamine oxidase and its inhibition. Ciba Foundation Symposium vol. 39 (1976), Elsevier 231-240
15. Heikkila R.E., Orlansky H., Mytilineou C., and Cohen G. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194 (1975) 47-56
16. Heinonen E.H., Anttila M.I., and Lammintausta R.A. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56 (1994) 742-749
17. Hutcheson D.M., Everitt B.J., Robbins T.W., and Dickinson A. The role of withdrawal in heroin addiction: enhances reward or promotes avoidance?. Nat Neurosci 4 (2001) 943-947
18. Kosten T.R., George T.P., and Kosten T.A. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 11 (2002) 491-499
19. Lamensdorf I., Youdim M.B., and Finberg J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67 (1996) 1532-1539
20. Li N., He S., Parrish C., Delich J., and Grasing K. Differences in morphine and cocaine reinforcement under fixed and progressive ratio schedules; effects of extinction, reacquisition and schedule design. Behav Pharmacol 14 (2003) 619-630
21. Maitre L., Delini-Stula A., and Waldmeier P.C. Relations between the degree of monoamine oxidase inhibition and some psychopharmaocological responses to monoamine oxidase and its inhibition. Ciba foundation symposium on monoamine oxidase and its inhibition (1976), North Holland, Amsterdam 247-276
22. Maki Y., Inoue T., Izumi T., Muraki I., Ito K., Kitaichi Y., et al. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur J Pharmacol 406 (2000) 411-418
23. Melega W.P., Cho A.K., Schmitz D., Kuczenski R., and Segal D.S. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J Pharmacol Exp Ther 288 (1999) 752-758
24. Mercuri N.B., Scarponi M., Bonci A., Siniscalchi A., and Bernardi G. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 17 (1997) 2267-2272
25. Navarro M., Fernandez-Ruiz J.J., Rodriguez de Fonseca F., Hernandez M.L., Cebeira M., and Ramos J.A. Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice. Pharmacol Biochem Behav 43 (1992) 603-608
26. Pierce R.C., and Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev 30 (2006) 215-238
27. Robinson D.S. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 36 (2002) 124-138
28. Rossetti Z.L., Hmaidan Y., and Gessa G. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221 (1992) 227-234
29. Shaham Y., Shalev U., Lu L., de Wit H., and Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (2002)
30. Spanagel R., and Heilig M. Addiction and its brain science. Addiction 100 (2005) 1813-1822
31. Stafford D., LeSage M.G., and Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139 (1998) 169-184
32. Tao R., and Auerbach S.B. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 68 (1995) 553-561
33. Tao R., Ma Z., and Auerbach S.B. Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther 286 (1998) 481-488
34. Waldmeier P.C., and Felner A.E. Deprenil, loss of selectivity for inhibition of b-type MAO after repeated treatment. Biochem Pharmacol 27 (1978) 801-806
35. Walters C.L., Aston-Jones G., and Druhan J.P. Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist. Neuropsychopharmacology 23 (2000) 307-315
36. Wang G.J., Volkow N.D., Fowler J.S., Logan J., Abumrad N.N., Hitzemann R.J., et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16 (1997) 174-182
37. Winger G.D., Yasar S., Negus S.S., and Goldberg S.R. Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther 56 (1994) 774-780
38. Youdim M.B., Gross A., and Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 (2001) 500-506